Costo-Utilidad De La Vacuna Contra El Virus De Papiloma Humano En Mujeres Peruanas

Resultado de la investigación: Contribución a una revistaArtículo originalrevisión exhaustiva

5 Citas (Scopus)

Resumen

Objetives. To estimate the cost-utility of the vaccine against the Human Papiloma Virus (HPV) in peruvian women after the application of the vaccine at 10 years of age. Materials and methods. A cost-utility analysis was performed using the Markov's hidden model in a hypothetical cohort of peruvian women, based on the information on epidemiological parameters, costs associated to uterine cervical cancer (UCC) and the efficacy and costs of the vaccine against the HPV. The vaccination costs were estimated from the Peruvian Ministry of Health perspective and were compared against the quality-adjusted life years (QALYs), using a discount rate of 5%. Results. The annual cost of the vaccination was USD 16'861,490, for the Papanicoau screening it was USD 3'060,793 and the costs associated to the UCC were USD 15'580,000. The incremental cost utility ratio (ICUR) was 6,775 USD/QALY. Conclusions. Vaccination against HPV can be cost-utility compared to not vaccinating.

Título traducido de la contribuciónCost- utility of the vaccine against the Human Papiloma Virus in peruvian women
Idioma originalEspañol
Páginas (desde-hasta)416-425
Número de páginas10
PublicaciónRevista Peruana de Medicina Experimental y Salud Publica
Volumen28
N.º3
DOI
EstadoPublicada - 2011
Publicado de forma externa

Palabras clave

  • Costs and cost analysis (source: MeSH NLM)
  • Inmunization
  • Papillomavirus vaccines
  • Uterine cervical neoplasms

Huella

Profundice en los temas de investigación de 'Costo-Utilidad De La Vacuna Contra El Virus De Papiloma Humano En Mujeres Peruanas'. En conjunto forman una huella única.

Citar esto